Among patients with DLL3 expression‐positive LCNEC, no marked difference was found in the five‐year OS or RFS between patients with adjuvant chemotherapy and those without it (surgery + chemotherapy vs. surgery alone, five‐year OS: 58.3% vs. 35.7% P = 0.36, five‐year RFS: 41.7% vs. 35.7% P = 0.74) (Fig. 4a,b). This evidence concerns the gene DLL3 and large cell neuroendocrine carcinoma.